CMIIU News and Press, CM Life Sciences II Inc. Unit From 06/21/21

A team with a track record of prior success has raised its largest SPAC yet. The SPAC is about two months old, meaning it is becoming more likely to do a deal going forward. Because of the track record and the reputation of the team, the warrants are trading relatively rich. ...

"If you own the turbo-charged growth stocks... you either need to steel yourself for the pain or cut your losses on the next sharp move up, because we're in a new market that’s very different from last year," Jim Cramer said in the latest episode of Mad Money. "What worked in 2020 hasn...

I operate two main portfolios: my "safe" portfolio and my high growth portfolio. This article will dissect and focus on my high-growth holdings. I generally like to invest in themes and tend to take a shotgun approach to my holdings in emerging sectors. I will list my holdings for 8 s...

SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of three independent directors to it...

CM Life Sciences II Inc. (Nasdaq: CMIIU) (the “ Company ”) today announced that holders of the Company’s units sold in its initial public offering may elect to separately trade the shares of Class A common stock and redeemable warrants included in its units comm...

Declining SPAC IPOs could indicate the SPAC bubble may have run its course. Brookfield Asset Management agrees to acquire Brookfield Property Partners after increasing its bid by 10%. Aggregate deal value in a highly competitive M&A space approaches $600 billion in Q1 202...

Special purpose acquisition company CM Life Sciences II Inc. (CMIIU) rallied for the fourth straight day Thursday, gaining as much as 15.4% intraday as Wall Street continued to endorse its plan to buy SomaLogic at a $1.2B valuation.CMIIU rose to as high as $14.77 during the session, although ...

CM Life Sciences II, Inc. is the second life-sciences-focused special purpose acquisition company from the Casdin-Meisters team launched in Feb 2021. CM Life Sciences II has announced its acquisition target as SomaLogic, a pioneer in proteomics technology, with the $651M transaction e...

CM Life Sciences II (CMIIU), the SPAC backed by activist  Keith Meister’s Corvex Management LP and life-sciences investor Casdin Capital, gained 11% in premarket trading after confirming a deal to take protein-analysis company SomaLogic public.Financing includes a $375M ...

Universe Pharmaceuticals (UPC) +113%.Humanigen (HGEN) +61% on positive Phase 3 data for COVID-19 therapy.Cyanotech Corporation (CYAN) +48%.Big Rock Partners Acquisition (BRPA) +42%.SeaChange International (SEAC) +34% on multi-million-dollar contract with broadband service provider.F...